🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

67 results for “Amgen Technology (Ireland) UC” Clear

  1. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen Technology (Ireland) UC

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  2. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen Technology (Ireland) UC

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  3. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen Technology (Ireland) UC

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  4. AMG 133, Placebo for AMG 133 (maridebart cafraglutide)

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  5. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen Technology (Ireland) UC

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  6. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  7. Apremilast, Apremilast, Apremilast

    Amgen Technology (Ireland) UC

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  8. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen Technology (Ireland) UC

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. CALCIUM FOLINATE, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, SOTORASIB, FLUOROURACIL

    Amgen Technology (Ireland) UC

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  10. DEXAMETHASONE, RITUXIMAB, BLINATUMOMAB, MERCAPTOPURINE, RITUXIMAB, BLINATUMOMAB, CYCLOPHOSPHAMIDE, PREDNISONE, CYTARABINE, IDARUBICIN, PREDNISOLONE, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PEGASPARGASE, DOXORUBICIN, CYTARABINE, DEXAMETHASONE, MERCAPTOPURINE, VINCRISTINE SULFATE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, VINCRISTINE SULFATE, ASPARAGINASE, CRISANTASPASE, METHOTREXATE SODIUM

    Amgen Technology (Ireland) UC

    Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults

    phase 3 small molecule active

    1 trial

  11. Dazodalibep

    Amgen Technology (Ireland) UC

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  12. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen Technology (Ireland) UC

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  13. EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled syringe, EVENITY 105 mg solution for injection in pre-filled pen, EVENITY 105 mg solution for injection in pre-filled pen

    Amgen Technology (Ireland) UC

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial

  14. Erenumab, Placebo for AMG 334

    Amgen Technology (Ireland) UC

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  15. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen Technology (Ireland) UC

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  16. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen Technology (Ireland) UC

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  17. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen Technology (Ireland) UC

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  18. OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID

    Amgen Technology (Ireland) UC

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  19. Ocrevus, ABP 692, Ocrevus 300 mg concentrate for solution for infusion

    Amgen Technology (Ireland) UC

    Relapsing-remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. Olpasiran, Placebo for AMG 890

    Amgen Technology (Ireland) UC

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  21. Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection

    Amgen Technology (Ireland) UC

    Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis

    phase 3 small molecule active

    1 trial

  22. Placebo for AMG 145, EVOLOCUMAB

    Amgen Technology (Ireland) UC

    Adults at high risk of cardiovascular events without prior MI or stroke.

    phase 3 small molecule active

    1 trial

  23. Placebo for AMG 334, Erenumab

    Amgen Technology (Ireland) UC

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  24. Placebo for AMG 890

    Amgen Technology (Ireland) UC

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources